Regen BioPharma Inc 8-K, filed Apr 9, 2021

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C.  20549

FORM8-K

CURRENTREPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2021

REGENBIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

CommissionFile No. 333-191725

711S. Carson Street, Suite 4, Carson City, Nevada, 89791

(Address of Principal Executive Offices)

(619)702 1404

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

| 1 |

| --- |

Item8.01 Other Events.

Regen Biopharma, Inc. (the “Company”) is in the process of preparing financial statements in order that Company may have such statements audited (in the case of Annual Financial Statements) and reviewed (in the case of Quarterly Financial Statements).

Upon completion of the aforementioned audits and reviews and preparation of the required reports, the Company intends file the following delinquent periodic reports with United States Securities and Exchange Commission:

| 2 |

| --- |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| 3 |

| --- |